BridgeBio Pharma, Inc. — Director's Dealing 2020

Nov 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-11-02

Reporting Person: HENDERSON MICHAEL THOMAS (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-02	Common Stock	M	10000	$1.05	Acquired	277751	Direct
2020-11-02	Common Stock	S	9500	$38.3263	Disposed	268251	Direct
2020-11-02	Common Stock	S	500	$38.9156	Disposed	267751	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-02	Stock Option (Right to Buy)	$1.05	M	10000	Disposed	2029-09-24	Common Stock (10000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.

F2: Represents the weighted average sale price of the shares sold from $37.80 to $38.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

F3: Represents the weighted average sale price of the shares sold from $38.86 to $38.97 per share.